Zhihao H. Lu

Key Laboratory Of Carcinogenesis And Translational Research
Beijing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 111 publications

Depleting S100A4 in Cancer-Associated Fibroblasts Reverses Cisplatin Resistance in Esophageal Cancer.

Depleting S100A4 in Cancer-Associated Fibroblasts Reverses Cisplatin Resistance in Esophageal Cancer.

Journal: ACS applied bio materials

Published: June 18, 2026

Guanylyl Cyclase 2C-Targeted Chimeric Antigen Receptor T-Cell Therapy in Patients With Metastatic Colorectal Cancer.

Guanylyl Cyclase 2C-Targeted Chimeric Antigen Receptor T-Cell Therapy in Patients With Metastatic Colorectal Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: June 04, 2026

Efficacy and Safety of DVDMS-Photodynamic Therapy for Dysphagia in Advanced Esophageal Cancer: A Phase II Clinical Trial.

Efficacy and Safety of DVDMS-Photodynamic Therapy for Dysphagia in Advanced Esophageal Cancer: A Phase II Clinical Trial.

Journal: Cancer science

Published: April 20, 2026

Allogeneic B7-H3-Targeted CAR Vδ1T-cell Therapy in Advanced Solid Tumors: A Phase I Study.

Allogeneic B7-H3-Targeted CAR Vδ1T-cell Therapy in Advanced Solid Tumors: A Phase I Study.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 03, 2025

Prognostic and therapeutic roles of specific genotypes through target-gene sequencing on gastroenteropancreatic neuroendocrine carcinoma.

Prognostic and therapeutic roles of specific genotypes through target-gene sequencing on gastroenteropancreatic neuroendocrine carcinoma.

Journal: The oncologist

Published: November 11, 2025

Reply to: "NOTCH1: A Potential New Biomarker in the Era of Immunotherapy?" and "Caution in Interpreting NOTCH1 Mutation as a Predictive Biomarker of Tislelizumab Response in Esophageal Squamous Cell Carcinoma".

Reply to: "NOTCH1: A Potential New Biomarker in the Era of Immunotherapy?" and "Caution in Interpreting NOTCH1 Mutation as a Predictive Biomarker of Tislelizumab Response in Esophageal Squamous Cell Carcinoma".

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 11, 2025

Immune-related adverse events between elderly patients with gastrointestinal and lung cancers: A real-world study.

Immune-related adverse events between elderly patients with gastrointestinal and lung cancers: A real-world study.

Journal: Chinese medical journal

Published: August 21, 2025

Impact of Helicobacter pylori infection on gut and intratumoral microbiome and its association with immunotherapy response in gastrointestinal cancer.

Impact of Helicobacter pylori infection on gut and intratumoral microbiome and its association with immunotherapy response in gastrointestinal cancer.

Journal: BMC medicine

Published: July 18, 2025

Development and validation of a clinical risk-prediction model for immune checkpoint inhibitor-related pneumonitis in patients with gastrointestinal cancer based on four machine learning algorithms.

Development and validation of a clinical risk-prediction model for immune checkpoint inhibitor-related pneumonitis in patients with gastrointestinal cancer based on four machine learning algorithms.

Journal: Chinese journal of cancer research = Chung-kuo yen cheng yen chiu

Published: July 15, 2025

Development of a multi-epitope mRNA vaccine targeting tumor-associated antigens for esophageal squamous cell carcinoma.

Development of a multi-epitope mRNA vaccine targeting tumor-associated antigens for esophageal squamous cell carcinoma.

Journal: NPJ vaccines

Published: June 27, 2025

NOTCH1 Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial.

NOTCH1 Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 03, 2025

An integrated prognosis prediction model based on real-word clinical characteristics for immunotherapy in advanced esophageal squamous cell carcinoma.

An integrated prognosis prediction model based on real-word clinical characteristics for immunotherapy in advanced esophageal squamous cell carcinoma.

Journal: Cancer immunology, immunotherapy : CII

Published: January 21, 2025

Showing 1-12 of 111

Last Updated: 09/26/2026